Abstract
Several new oral anticoagulants are now on the Swiss market and the general practitioner faces new challenges regarding the management of these new drugs. This consensus document aims to answer to the most frequently asked questions regarding rivaroxaban and covers different topics such as indications, initiation of treatment, drug-drug interactions and perioperative management.
Publication types
-
Consensus Development Conference
-
English Abstract
MeSH terms
-
Administration, Oral
-
Anticoagulants / therapeutic use*
-
General Practice*
-
Humans
-
Morpholines / therapeutic use*
-
Orthopedic Procedures / adverse effects
-
Rivaroxaban
-
Switzerland
-
Thiophenes / therapeutic use*
-
Treatment Outcome
-
Venous Thromboembolism / prevention & control*
Substances
-
Anticoagulants
-
Morpholines
-
Thiophenes
-
Rivaroxaban